总时间（秒）：115.07
问答时间（秒）：112.51

<think>
Okay, let's start by extracting the relevant information from the provided text. The user wants me to assess the functional evidence for each variant mentioned in the paper using the ACMG guidelines. First, I need to identify all the variants discussed.

The abstract mentions the Y1699C mutation in LRRK2 and compares its GTPase activity to R1441C and T1348N mutants. The introduction also lists R1441C/G/H, Y1699C, G2019S, I2020T as pathogenic. However, the functional data in the abstract specifically talks about Y1699C, R1441C, and T1348N. So, the variants to consider are Y1699C, R1441C, and T1348N. G2019S and I2020T are mentioned but not discussed in the functional data provided here.

Now, for each variant, I need to extract the functional evidence. For Y1699C, the paper states that it decreases GTPase activity, similar to R1441C and T1348N. The mechanism involves weakened ROC-COR dimerization and strengthened intra-molecular interaction. R1441C is mentioned as a pathogenic mutant with decreased GTPase activity. T1348N is a dysfunctional mutant with decreased activity too.

Next, parsing the variant info. For Y1699C: Gene is LRRK2, Protein Change ref is Y, alt is C, position 1699. Variant string is LRRK2 Y1699C. R1441C: ref R, alt C, position 1441. T1348N: ref T, alt N, position 1348.

Applying the ACMG flowchart. Step 1: The disease mechanism is defined as LRRK2 mutations causing PD through altered GTPase activity and protein interactions. The paper clearly states this, so judgment is yes.

Step 2: The assays used (GTPase activity, dimerization, competition assay) are relevant to the disease mechanism. So judgment is yes.

Step 3a: Controls. The paper mentions R1441C and T1348N as controls. However, it's unclear if multiple replicates were done. The text says "comparable to the decrease observed for the R1441C... and T1348N dysfunctional mutant." But there's no explicit mention of replicates or control groups. So maybe 3a is no.

Then, step 3b: Is the assay accepted or validated? The assays (GTPase activity, dimerization) are standard in the field. So judgment yes, leading to PS3_supporting.

Step 4: Statistical analysis. The paper doesn't mention statistical tests or OddsPath. So step 4b: How many controls? The paper uses R1441C and T1348N. That's two controls. So total of 2, which is less than 10. So PS3_supporting.

For R1441C, the same steps apply. It's a known pathogenic variant, but in the paper, it's used as a control. However, the functional evidence is about Y1699C. So for R1441C, the functional evidence is already established elsewhere, but in this paper, it's used as a control. So the assessment would be similar but maybe different.

Wait, but the user wants to assess each variant mentioned with functional data. The paper's functional data is about Y1699C, comparing it to R1441C and T1348N. So R1441C and T1348N are used as controls. Therefore, for R1441C and T1348N, the functional evidence is not the main focus here but used as controls. However, since the paper does mention their effects, perhaps they should be included.

But the user's instruction says to extract for each variant that has functional data. The functional data here is for Y1699C, R1441C, and T1348N. So all three need to be assessed.

For R1441C, the paper states it's a pathogenic mutant with decreased GTPase activity. The steps would be similar. Controls: the paper uses T1348N and Y1699C as controls. So again, step 3a may not have sufficient controls. But since the assays are accepted, step 3b applies. Then, step 4b: number of controls is two (Y1699C and T1348N), leading to PS3_supporting.

Same for T1348N. The paper uses R1441C and Y1699C as controls. So same reasoning.

Now, for each variant, the functional evidence aim is pathogenic, as the decreased GTPase activity is associated with disease.

In the JSON structure, each variant is an object. The assessment steps need to be filled out for each variant.

For Y1699C:

Step 1: yes, disease mechanism is defined.

Step 2: yes, assays are relevant.

Step 3a: no, because the paper doesn't explicitly mention replicates or control groups. So move to 3b.

Step 3b: assays are accepted, so PS3_supporting.

Step 4: statistical analysis not present, so step 4b. Number of controls is 2 (R1441C and T1348N), so PS3_supporting.

For R1441C:

Step 1: yes.

Step 2: yes.

Step 3a: the paper uses Y1699C and T1348N as controls. But the functional data for R1441C is not the main focus. The paper's main variant is Y1699C. So for R1441C, the functional evidence is established elsewhere, but in this paper, it's used as a control. However, the user wants to assess all variants with functional data. Since the paper mentions R1441C's effect, same steps apply. Controls are Y1699C and T1348N (2), so PS3_supporting.

Same for T1348N.

Now, constructing the JSON for each variant.
</think>

```json
[
  {
    "variant": "LRRK2 Y1699C",
    "protein_change": {
      "ref": "Y",
      "alt": "C",
      "position": 1699
    },
    "functional_evidence": {
      "effect": "Decreased GTPase activity, weakened ROC-COR dimerization, strengthened intra-molecular interaction",
      "controls_used": ["LRRK2 R1441C", "LRRK2 T1348N"]
    },
    "acmg_assessment": {
      "step1": {
        "question": "Is the disease mechanism defined?",
        "answer": "Yes. LRRK2 mutations disrupt GTPase activity and protein interactions, leading to PD.",
        "judgment": "Yes"
      },
      "step2": {
        "question": "Are the assays relevant to the disease mechanism?",
        "answer": "Yes. GTPase activity, dimerization, and competition assays are directly tied to LRRK2's role in PD.",
        "judgment": "Yes"
      },
      "step3a": {
        "question": "Are variant controls and replicates sufficient?",
        "answer": "No. The paper does not explicitly mention statistical replicates or control groups for Y1699C.",
        "judgment": "No"
      },
      "step3b": {
        "question": "Is the assay accepted/validated?",
        "answer": "Yes. GTPase activity and dimerization assays are standard in LRRK2 research.",
        "judgment": "Yes",
        "strength": "Max PS3_supporting"
      },
      "step4": {
        "step4b": {
          "question": "How many total variant controls are used?",
          "answer": "2 (R1441C and T1348N).",
          "judgment": "Fewer than 10.",
          "strength": "Max PS3_supporting"
        }
      },
      "functional_evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "Pathogenic"
    }
  },
  {
    "variant": "LRRK2 R1441C",
    "protein_change": {
      "ref": "R",
      "alt": "C",
      "position": 1441
    },
    "functional_evidence": {
      "effect": "Decreased GTPase activity (used as a control for Y1699C comparison)",
      "controls_used": ["LRRK2 Y1699C", "LRRK2 T1348N"]
    },
    "acmg_assessment": {
      "step1": {
        "question": "Is the disease mechanism defined?",
        "answer": "Yes. LRRK2 mutations disrupt GTPase activity and protein interactions, leading to PD.",
        "judgment": "Yes"
      },
      "step2": {
        "question": "Are the assays relevant to the disease mechanism?",
        "answer": "Yes. GTPase activity and dimerization assays are directly tied to LRRK2's role in PD.",
        "judgment": "Yes"
      },
      "step3a": {
        "question": "Are variant controls and replicates sufficient?",
        "answer": "No. The paper does not explicitly mention statistical replicates or control groups for R1441C.",
        "judgment": "No"
      },
      "step3b": {
        "question": "Is the assay accepted/validated?",
        "answer": "Yes. GTPase activity and dimerization assays are standard in LRRK2 research.",
        "judgment": "Yes",
        "strength": "Max PS3_supporting"
      },
      "step4": {
        "step4b": {
          "question": "How many total variant controls are used?",
          "answer": "2 (Y1699C and T1348N).",
          "judgment": "Fewer than 10.",
          "strength": "Max PS3_supporting"
        }
      },
      "functional_evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "Pathogenic"
    }
  },
  {
    "variant": "LRRK2 T1348N",
    "protein_change": {
      "ref": "T",
      "alt": "N",
      "position": 1348
    },
    "functional_evidence": {
      "effect": "Decreased GTPase activity (used as a control for Y1699C comparison)",
      "controls_used": ["LRRK2 Y1699C", "LRRK2 R1441C"]
    },
    "acmg_assessment": {
      "step1": {
        "question": "Is the disease mechanism defined?",
        "answer": "Yes. LRRK2 mutations disrupt GTPase activity and protein interactions, leading to PD.",
        "judgment": "Yes"
      },
      "step2": {
        "question": "Are the assays relevant to the disease mechanism?",
        "answer": "Yes. GTPase activity and dimerization assays are directly tied to LRRK2's role in PD.",
        "judgment": "Yes"
      },
      "step3a": {
        "question": "Are variant controls and replicates sufficient?",
        "answer": "No. The paper does not explicitly mention statistical replicates or control groups for T1348N.",
        "judgment": "No"
      },
      "step3b": {
        "question": "Is the assay accepted/validated?",
        "answer": "Yes. GTPase activity and dimerization assays are standard in LRRK2 research.",
        "judgment": "Yes",
        "strength": "Max PS3_supporting"
      },
      "step4": {
        "step4b": {
          "question": "How many total variant controls are used?",
          "answer": "2 (Y1699C and R1441C).",
          "judgment": "Fewer than 10.",
          "strength": "Max PS3_supporting"
        }
      },
      "functional_evidence_strength": "PS3_supporting",
      "functional_evidence_aim": "Pathogenic"
    }
  }
]
```